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Abstract  
Introduction. Owing to its well-established ergogenic potential, creatine is a highly popular food 
supplement in sports. As an oral supplement, creatine is considered safe and ethical. However, 
no data exist on the safety of creatine on lung function in athletes. The aim of this project was to 
evaluate the effects of a standard course of creatine on the airways of youth elite athletes. 
Methods. Nineteen elite soccer players, aged 16-21yr, completed a stratified, randomized, 
double-blind, placebo-controlled, parallel-group trial. The creatine group (n=9) ingested 0.3 
g/kg/d of creatine monohydrate (CM) for 1wk (loading phase) and 5 g/d for 7wk (maintenance 
phase), and the placebo group (n=10) received the same dosages of maltodextrin. Airway 
inflammation (assessed by exhaled nitric oxide, FENO) and airway responsiveness (to dry air 
hyperpnoea) were measured pre- and post-supplementation. Results. Mild, unfavorable changes 
in FENO were noticed by trend over the supplementation period in the CM group only (P=0.056 
for interaction, η2=0.199), with a mean group change of 9  13 ppb in the CM group versus -5  
16 ppb in the placebo group (P=0.056, d=0.695). Further, the maximum fall in forced expiratory 
volume in 1 sec (FEV1) after dry air hyperpnoea was larger by trend post-supplementation in the 
CM group compared to the placebo group: 9.7  7.5% versus 4.4  1.4%, respectively (P=0.070, 
d=0.975). These adverse effects were more pronounced when atopic players only (n=15) were 
considered. Conclusion. Based on the observed trends and medium-to-large effect sizes, we 
cannot exclude that creatine supplementation has an adverse effect on the airways of elite 
athletes, particularly in those with allergic sensitization. Further safety profiling of the ergogenic 
food supplement is warranted.  
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Abstract  
Introduction. Owing to its well-established ergogenic potential, creatine is a highly popular food 
supplement in sports. As an oral supplement, creatine is considered safe and ethical. However, 
no data exist on the safety of creatine on lung function in athletes. The aim of this project was to 
evaluate the effects of a standard course of creatine on the airways of youth elite athletes. 
Methods. Nineteen elite soccer players, aged 16-21yr, completed a stratified, randomized, 
double-blind, placebo-controlled, parallel-group trial. The creatine group (n=9) ingested 0.3 
g/kg/d of creatine monohydrate (CM) for 1wk (loading phase) and 5 g/d for 7wk (maintenance 
phase), and the placebo group (n=10) received the same dosages of maltodextrin. Airway 
inflammation (assessed by exhaled nitric oxide, FENO) and airway responsiveness (to dry air 
hyperpnoea) were measured pre- and post-supplementation. Results. Mild, unfavorable changes 
in FENO were noticed by trend over the supplementation period in the CM group only (P=0.056 
for interaction, η2=0.199), with a mean group change of 9  13 ppb in the CM group versus -5  
16 ppb in the placebo group (P=0.056, d=0.695). Further, the maximum fall in forced expiratory 
volume in 1 sec (FEV1) after dry air hyperpnoea was larger by trend post-supplementation in the 
CM group compared to the placebo group: 9.7  7.5% versus 4.4  1.4%, respectively (P=0.070, 
d=0.975). These adverse effects were more pronounced when atopic players only (n=15) were 
considered. Conclusion. Based on the observed trends and medium-to-large effect sizes, we 
cannot exclude that creatine supplementation has an adverse effect on the airways of elite 
athletes, particularly in those with allergic sensitization. Further safety profiling of the ergogenic 
food supplement is warranted.  
Keywords: creatine monohydrate; football; airway inflammation; airway hyperresponsiveness; 
exhaled nitric oxide; eucapnic voluntary hyperpnoea
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Introduction 1 
Creatine is one of the most popular food supplements used by athletes (1); it is used in a wide 2 
variety of sports and at all levels [e.g. about a third of English professional soccer players (2) and 3 
the same percentage of American children and adolescents (3) declare using the supplement]. 4 
The popularity of creatine stems from the fact that the ergogenic potential of creatine is 5 
supported by strong scientific evidence (1) and its mechanisms of action are well understood. 6 
Since the early 1990s (4), studies have consistently shown that creatine supplementation raises 7 
intramuscular creatine stores, thereby helping to maintain ATP availability during exercise and 8 
enhancing high-intensity (anaerobic) exercise capacity (1). That creatine is not prohibited by the 9 
governing bodies of sport (including the World Anti-Doping Agency), and is purported to be 10 
safe (1,5) likely contributes to its widespread use.  11 
  12 
The recognized potential of creatine to stimulate muscle strength and power, to increase muscle 13 
volume/fat-free mass, and to stimulate recovery from exercise (5) make it particularly attractive 14 
in sports with repeated short bursts of high-intensity activity. Evidence of an ergogenic effect of 15 
the supplement has repeatedly been reported in team sports, including soccer (6). Further, in 16 
semi-professional soccer players, a standard, 8-wk course of creatine monohydrate (CM) 17 
supplementation has been reported to be safe (7). However, no study has so far evaluated the 18 
possible adverse effect of creatine on lung function in athletes. This is particularly striking 19 
considering that, in an animal model of asthma, creatine has been shown to exacerbate allergic-20 
induced lung inflammation, airway remodeling and airway hyperresponsiveness (AHR) (8). 21 
Creatine is thought to initiate an important cellular signaling pathway in the airway epithelium 22 
that results, amongst others, in: an increase infiltration of inflammatory cells to the airways; an 23 
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increased number of mucus-synthesizing cells; and an upregulation of airway remodeling (9). 24 
Similar features have been observed in bronchial biopsies of elite athletes (10,11), many of 25 
whom suffer from asthma/AHR (10-13). 26 
 27 
Asthma is a chronic inflammatory disorder of the airways, with associated allergic sensitization, 28 
that is characterized by reversible airway obstruction and AHR to a wide range of stimuli 29 
(including exercise). In elite sports, asthma/AHR is the most common chronic medical condition, 30 
with an overall prevalence of 8% (12). The distribution of asthma/AHR in sport is however 31 
largely skewed, with the highest prevalence rates observed in endurance sports and/or in 32 
disciplines performed in unfavorable environments (e.g. swimming or cross-country skiing) (12-33 
14). Nonetheless, recent reports have highlighted that team sport players, such as soccer (15,16) 34 
and rugby players (17,18), may also commonly suffer from asthma/AHR. Given the high 35 
prevalence of asthma-related problems and the widespread use of creatine supplements in elite 36 
sport, it is important to identify any adverse effects that ergogenic food supplements may have 37 
on lung function in this population.  38 
 39 
The aim of our study was therefore to evaluate the effects of a standard course of creatine 40 
supplementation on the respiratory health of youth elite athletes. Our hypothesis was that 41 
ingestion of a standard dose of creatine monohydrate for 8wk, in combination with intensive 42 
soccer-specific training, increases airway inflammation and airway responsiveness. 43 
44 
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Methods 45 
Study participants 46 
Nineteen under 18 (U18) and nine under 21 (U21), non-smoking, male, elite soccer players from 47 
Watford Football Club (FC) Academy agreed to take part in this project. Participants completed 48 
a medical questionnaire before the start of the study to check that none were currently injured or 49 
on medication [except for asthma and/or exercise-induced bronchoconstriction (EIB)]. On 50 
enrolment, one participant disclosed doctor-diagnosed asthma and, based on skin prick testing 51 
(cf. methodology below), nineteen (68%) had evidence of atopy. The study was approved by the 52 
Research Ethics Committee from the School of Sport & Education, Brunel University London 53 
(#RE69-13). All participants gave informed, written consent before taking part. 54 
 55 
Study design   56 
A stratified, randomized, double-blind, placebo-controlled, parallel-group trial of creatine 57 
supplementation was conducted over 8wk during the first half of the English competitive season 58 
(Oct-Dec). Stratified randomization was used to ensure equal distribution between groups of: i) 59 
participants with allergic sensitization (atopy) or doctor-diagnosed allergic asthma and ii) U18 60 
and U21 players. Atopy was assessed at study entry by standard skin prick test (19), with the 61 
following allergens tested: house dust mite, timothy grass, silver birch, dog and cat hair. In line 62 
with current international recommendations (19), wheal diameters ≥3 mm were considered as 63 
positive.  64 
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All players abstained from caffeine and alcohol on the day of the tests, from exercise for at least 65 
4 hours, and from anti-histamines for 72 h. To control for diurnal variation in lung function, all 66 
tests were conducted in the morning / early afternoon. 67 
 68 
Supplementation  69 
Participants were randomized into groups by an independent third party, using a random number 70 
generator. Allergic and non-allergic players, as well as U18 and U21 players were allocated, in 71 
equal numbers, to the creatine and placebo groups. A typical creatine monohydrate (CM) 72 
supplementation protocol was followed (1), whereby participants ingested 0.3 g/kg/d of CM 73 
(MyProtein, Informed Sports Range, 100% pure) during a 1-wk loading phase. The placebo 74 
group received the same dosage of maltodextrin (MyProtein, Informed Sports Range, 100% 75 
pure). The supplement was combined with 90 g of the participant’s usual protein drink (Maxiraw 76 
Protein Complex; 60% whey protein concentrate, 20% soy protein isolate, 20% micellar casein) 77 
provided to the players at Watford FC Academy, and ingested in four daily 150 ml intakes. This 78 
was followed by a 7-wk maintenance phase during which players ingested 5 g/day of CM, or of 79 
placebo, mixed up in 30 g of protein drink, and taken at the end of their daily training session or 80 
after games (at the weekend). To ensure adherence, the protein with supplement drinks were 81 
prepared daily by the Head Academy Sport Scientist (PS) at Watford FC Academy and handed 82 
out directly to the players at the required times (except on Sundays, when players were provided 83 
with shakers to take home).  84 
Body mass of the participants was measured using a calibrated electronic scale pre- and post-85 
supplementation. Body composition was assessed via skinfold measurement. In line with the 86 
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International Society for the Advancement of Kinanthropometry International Society for the 87 
Advancement of Kinanthropometry (ISAK), eight sites (i.e. tricep, sub-scapular, bicep, iliac 88 
crest, supra-spinal, abdominal, front thigh and medial calf) were measured. All measurements 89 
were taken by a Level 1 ISAK qualified researcher (with an average technical error of 90 
measurement of 1.50 ± 0.31%).      91 
Diet was not standardized, but participants were asked not to change their dietary habits during 92 
the course of the study. None of the players declared using creatine supplements in the three 93 
months prior to the study. 94 
Daily record of asthma symptoms, upper or lower respiratory tract infection symptoms, use of 95 
asthma reliever medication (salbutamol), and other potential side effects (e.g. muscle cramps, 96 
musculo-skeletal injury, gastro-intestinal discomfort) were logged for all players. 97 
 98 
Training programme 99 
This research did not interfere with the training schedule devised by the players’ coaches. The 8-100 
wk training programme included ~11 h per week of soccer specific training (i.e. technical and 101 
tactical exercises), with little strength and conditioning work (1 session of 50 min per week). 102 
As part of the Football League Youth Alliance, the U18 team had regular match fixtures over the 103 
course of the trial. Further, some the U21 players played for Watford FC first team (which, at the 104 
time of the study, was competing in the English Football League Championship). 105 
 106 
  107 
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Lung health assessment 108 
All the tests below were performed twice: once before and once after the 8wk supplementation 109 
period.  110 
Airway inflammation. Fractional nitric oxide in exhaled breath (FENO) was measured at rest 111 
using NIOX VERO (Aerocrine, Solna, Sweden) and was used as a non-invasive marker of 112 
airway inflammation (20). Players were asked to refrain from exercising, eating and drinking for 113 
an hour prior to the FENO measurements (21). As per standard recommendations (21), at least 114 
two measurements agreeing within 10% of each other were recorded, and the mean of the two 115 
values were calculated and used for analysis.  116 
Lung function. Standard spirometry was performed at rest in all players using the MicroLoop 117 
spirometer (Micromedical, Kent, UK) to determine baseline lung volume and expiratory flow 118 
rates. In accordance with the international recommendations (22), at least three technically 119 
acceptable forced vital capacity (FVC) manoeuvers were performed (up to a maximum of eight), 120 
with a minimum of two reproducible recordings [difference ≤150 ml for forced expiratory 121 
volume in 1 sec (FEV1) and FVC]. The highest FEV1 and FVC readings were kept for analysis. 122 
Forced expiratory flow between 25 and 75% of FVC (FEF25-75) was taken from the reproducible 123 
maneuver with the highest sum ‘FEV1+FVC’. The highest peak expiratory flow from all 124 
acceptable maneuvers was kept for analysis. Predicted values were calculated from the GLI-2012 125 
equations (23). 126 
Airway hyperresponsiveness (AHR). A standard 6-min eucapnic voluntary hyperpnoea (EVH) 127 
test with dry air was used to estimate the degree of airway responsiveness. The test was 128 
performed on a commercially available system (EucapSys, SMTEC, Nyon, Swiss) and involved 129 
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6 min of heavy breathing of a dry gas mixture containing 5% CO2, 21% O2, and balance nitrogen 130 
(24). Pre-supplementation, the target ventilation (VE) was set at 85% of predicted maximum 131 
voluntary ventilation (MVV) (24), calculated as resting FEV1 multiplied by thirty. Post-132 
supplementation, the target VE was set at the achieved level during the initial test. Participants 133 
failing to achieve the minimal recommended threshold of 60% MVV (24) were noted and 134 
discussed in the results section. Prior to, and at 2, 5, 10, 15 and 20 min of recovery, FVC 135 
maneuvers were performed in duplicate. The best FEV1 from reproducible measurements were 136 
kept for analysis. The maximal fall in FEV1 post-EVH (expressed as % difference from baseline) 137 
was calculated as an index of airway responsiveness. A test was considered positive for EIB if 138 
FEV1 fell by ≥10% from baseline over two consecutive time points (24).  139 
 140 
Data analysis 141 
Sample size. FENO was the primary outcome measure. The statistical power was set at 80% and 142 
the alpha level at 5%. To detect a 10 ppb difference in FENO between the CM and placebo 143 
groups post-supplementation [in non-inflamed airways, a change of 10 ppb being considered 144 
clinically meaningful (20)], with a within-group standard deviation of 6 ppb and a ratio of 145 
control to experimental participants of one, we calculated that a sample size of 14 players would 146 
be required (i.e. seven players per group). Taking account of an estimated drop-out rate of 30%, 147 
a minimum of twenty players was required. 148 
Statistical analysis. Normal distribution was examined using the Shapiro-Wilk test. Data was 149 
analyzed using unpaired t-tests for between-group comparisons at the start of the trial and for 150 
changes over the supplementation period (Δ values). Two-way repeated measures analysis of 151 
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variances (RM-ANOVA), with ‘group’ and ‘time’ as main factors, were used to test between- 152 
and within-group differences during the trial. FENO data had skewed distribution. As RM-153 
ANOVA are robust and can tolerate data that is non-normally distributed with only a small effect 154 
on the Type I error rate, the statistical test was however retained. Spearman correlation 155 
coefficient was calculated to determine the relationship between baseline FENO and change in 156 
FENO following supplementation with CM. Considering that some previous investigations 157 
indicated that the deleterious effects of creatine may be specific to sensitized animals (8), post-158 
hoc analyses were conducted (following the same procedures as described above) in atopic 159 
players only (n=7 in the CM group and n=8 in the placebo group). The significance level was set 160 
at P<0.05. A trend for statistical significance was deemed at P<0.10. Effect size was calculated 161 
via partial eta-squared values (η2) for ANOVA and Cohen’s d for t-tests. The magnitude of effect 162 
sizes was classified as small, medium and large for η2 >0.01, 0.06 and 0.14, respectively, and for 163 
d >0.2, 0.5 and 0.8, respectively (25). Data were analyzed with SPSS 24 for Windows (SPSS, 164 
Chicago, IL). Unless otherwise stated, data are presented as group mean values ± SD.  165 
  166 
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Results 167 
Participant characteristics 168 
Twenty eight players (19 U18 and 9 U21) were initially recruited, of whom nineteen completed 169 
the study. Details regarding participant withdrawals are provided in the CONSORT diagram 170 
(Figure 1). The only player with doctor-diagnosed asthma (treated by inhaled corticosteroids and 171 
inhaled beta2-agonist at the time of the study) withdrew due to an asthma exacerbation prior to 172 
randomization. Out of the nineteen players who completed the full trial (13 U18 and 6 U21), nine 173 
were in the CM group and ten in the placebo group.  174 
At study entry, participants were aged 17.4 ± 1.6 yr, had a stature of 178.3 ± 5.6 cm and a body 175 
mass of 73.7 ± 5.3 kg. No group differences were noted for age or anthropometry (Table 1). 176 
Eight weeks of CM or placebo supplementation did not significantly change the body mass of 177 
the players (P=0.421): in the CM group 75.7 ± 4.6 kg pre- versus 75.7 ± 4.6 kg post-178 
supplementation, and in the placebo group 72.0 ± 5.5 kg pre- versus 72.3 ± 5.5 kg post-179 
supplementation. A significant time effect was however noticed for body composition (P=0.002, 180 
η2=0.436), with the sum of eight skinfolds reduced from 64  15 mm to 61  15 mm post-181 
supplementation (and no group or interaction effect). The relative reduction in skinfold thickness 182 
was of 5.5 ± 5.0% in the CM group and of 4.4 ± 6.1% in the placebo group (P=0.678). 183 
Fifteen (79%) players were atopic (Table 1), with grass being the most common allergen players 184 
were sensitized to. Twelve (63%) players were positive to grass, six (32%) to house dust mite, 185 
five (26%) to dog hair, five (26%) to cat hair, and two (11%) to silver birch.  186 
One participant reported minor gastro-intestinal discomfort during the supplementation period; 187 
he was in the CM group. None of the other players reported any side effects from ingesting the 188 
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supplements. Two players reported a history of respiratory symptoms on exertion (i.e. chest 189 
tightness with/without cough) (Table 1), with one assigned to the CM group; neither of them 190 
reported an exacerbation of these symptoms or usage of asthma drugs over the supplementation 191 
period.  192 
 193 
FENO 194 
The RM-ANOVA revealed no group or time effect for FENO, but there was a trend for an 195 
interaction effect, with a P value of 0.056 and a η2 value of 0.199 (the latter indicating a large 196 
effect size). Post-hoc tests showed that FENO did not significantly change over the 197 
supplementation period in the placebo group (P=0.374), but there was a trend, with a medium 198 
effect size, for an increase in the CM group (P=0.071, d=0.695) (Figure 2). A statistical trend, 199 
with a large effect size in the direction of an unfavorable change in FENO following CM (Δ 200 
FENO = 9  13 ppb) compared to PLA (Δ FENO = -5  16 ppb) was also observed (P=0.056, 201 
d=0.950) (Figure 3). A significant positive relationship was noted between baseline FENO and Δ 202 
FENO in the CM group (rs
2=0.460, P=0.045). 203 
 204 
Resting lung function 205 
Resting lung function was normal (i.e. > lower limit of normal) in all the players, except one 206 
(Table 1, ID#14). This U18 player reported respiratory symptoms during strenuous exercise and 207 
had a family history of asthma, but no previous doctor diagnosis of asthma and/or EIB. No 208 
statistically significant differences in resting spirometry were observed between groups and/or 209 
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times (i.e. pre- to post-supplementation) (Table 2). While there was a trend for athletes in the 210 
CM group to have a larger resting FVC (P=0.053, η2=0.203), this trend disappeared when the 211 
data was normalized for age, stature and ethnicity (FVC % pred.) (Table 2). 212 
 213 
Airway hyperresponsiveness 214 
During the EVH tests, players sustained a mean VE of 114  23 Lmin-1 pre- and 115  25 Lmin-215 
1 post-supplementation in the CM group, and 94  18 Lmin-1 pre- and 96  17 Lmin-1 post-216 
supplementation in the placebo group. The statistical trend in the direction of a greater VE in the 217 
CM compared to the placebo group (P=0.063; η2=0.188) disappeared when the data was 218 
expressed as % of predicted MVV (P=0.514). VE was 71 ± 10% of predicted MVV pre- and 73 ± 219 
11% of predicted MVV post-supplementation for the CM group versus 68 ± 13% of predicted 220 
MVV pre- and 69 ± 13% of predicted MVV post-supplementation for placebo group. The 221 
supplementation had no impact on VE (i.e. no time or interaction effect). Three U18 players were 222 
unable to reach the minimum target VE of ≥60% of predicted MVV pre-supplementation (with 223 
recorded VE at 59, 58 and 37% of predicted MVV). Post-supplementation, two of these players 224 
reached the minimum threshold, while the latter only managed 40% of predicted MVV. 225 
The RM-ANOVA revealed no significant group or time effect on the maximum fall in FEV1 226 
post-EVH, but a trend for an interaction effect was noticed (P = 0.086 and η2 = 0.163, large 227 
effect size). Post-hoc tests showed no significant changes in the fall in FEV1 over the 228 
supplementation period in the CM group but a trend, with a medium effect size, for a reduced 229 
fall in FEV1 in the placebo group (P=0.060, d=0.679) (Figure 4). Further, the fall in FEV1 230 
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recorded post-supplementation was larger by trend, with a large effect size, in the CM group (9.7 231 
 7.5%) compared to the placebo group (4.4  1.4%) (P=0.070, d=0.975) (Figure 4).  232 
At an individual level, three players (Table 1, ID#2,8&14) had a ≥10% fall in FEV1 over at least 233 
two consecutive time points after EVH (consistent with a diagnosis of EIB) pre-supplementation; 234 
two of these players (both under CM) had also a sustained fall in FEV1 post-supplementation 235 
(Figure 4). None of the three players with a positive EVH test had a history of asthma and/or 236 
EIB, but they all had abnormally high FENO values (Table 1). The player who was positive for 237 
EIB pre-supplementation but negative post-supplementation (Table 1, ID#14) was the one who 238 
had an abnormally low lung function at rest (at both time points) and who reported respiratory 239 
symptoms during exercise; his data were consistent with a diagnosis of mild asthma. Another 240 
player in the CM group who reported occasional respiratory symptoms during exercise (Table 1, 241 
ID#9) had a borderline response to EVH (i.e. 9% fall in FEV1 pre-supplementation and a non-242 
sustained 11% fall post-supplementation) and markedly increased FENO levels at both time 243 
points (84 and 96 ppb pre- and post-supplementation, respectively); his overall profile was 244 
therefore suggestive of mild, seasonal EIB. Altogether, this suggests that four out of the nineteen 245 
players (21%) had undiagnosed asthma and/or EIB.  246 
  247 
Post-hoc analysis in atopic participants (n=15) 248 
Similar to the whole group analysis, a RM-ANOVA conducted on FENO measurements revealed 249 
a significant interaction effect in the atopic players (P=0.029 and η2= 0.317). Post-hoc tests 250 
showed a trend, with a large effect size, for FENO to increase following supplementation with 251 
CM (P=0.072, d=0.824) and no change following placebo (P=0.248) (Figure 2). The statistical 252 
15 
 
trend for a between-group difference for the change in FENO over the supplementation period 253 
was significant in atopic players (P=0.029), with a large effect size (d=1.272): Δ FENO = 254 
12 ± 14 ppb in the CM group versus -6 ± 14 ppb in the placebo group  (Figure 3). 255 
Trend for within- and between-group differences in airway responsiveness reached statistical 256 
significance when atopic athletes only were entered into the analysis. For the maximum fall in 257 
FEV1 post-EVH, the RM-ANOVA revealed a significant interaction effect (P=0.027 and η2= 258 
0.323). Post-hoc tests showed no significant changes in the fall in FEV1 over the 259 
supplementation period in the CM group (P=0.297) but a reduced fall in FEV1 in the placebo 260 
group (P=0.041, d=0.852) (Figure 4). Consequently, the change in AHR following the 261 
supplementation period was significantly different between the atopic players supplemented with 262 
CM (-1.3 ± 3.0%) and placebo (2.3 ± 2.6%) (P=0.027, d=1.289). Further, the fall in 263 
FEV1 recorded post-supplementation was significantly larger (P=0.026, d=1.295) in the CM 264 
group (11.4 ± 7.6%) compared to the placebo group (4.5 ± 1.5%) in atopic players (Figure 4). 265 
 266 
Discussion 267 
The aim of this study was to determine whether creatine supplementation in combination with 268 
intensive training increased airway inflammation and airway responsiveness in elite athletes. In 269 
soccer Academy players, trends for unfavorable changes in FENO (an indirect marker of airway 270 
inflammation) were noticed after daily ingestion of CM for 8wk. A statistical trend in the 271 
direction of a greater fall in FEV1 after dry air hyperpnoea – indicative of increased airway 272 
responsiveness – was also observed following CM supplementation compared to placebo. These 273 
effects were more pronounced when atopic individuals only were entered into the statistical 274 
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analysis. Therefore, our findings highlight possible adverse effects of the popular ergogenic food 275 
supplement on the airways of elite athletes, particularly in those with allergic sensitization.  276 
 277 
The safety of creatine has widely been investigated in athletes through serum and urinary 278 
markers of metabolic, hepatic, renal and muscular function [e.g. (1,7)]. The general consensus is 279 
that, at the recommended dosage, creatine is safe (1,5). However, up to now, the effects of 280 
creatine supplements on lung function in athletes have not been assessed. In our study, trends 281 
(with medium-to-large effect sizes) for an increase in FENO [a well-established marker for 282 
eosinophilic airway inflammation in humans (20)] were observed after 8wk of CM 283 
supplementation in a mixed group of atopic and non-atopic athletes. When atopic athletes 284 
(representing 80% of the study population) were analyzed separately, statistical significance in 285 
favor of a larger increase in FENO post-supplementation in the CM compared to the placebo 286 
group was noted. This is in keeping with data obtained in a murine model for allergic asthma (i.e. 287 
ovalbumin-treated mice) (8) that showed an increase in airway inflammation (as identified by 288 
infiltration of eosinophils and of pro-inflammatory cytokines within the airways) and occurrence 289 
of airway remodeling following 32 days of creatine supplementation. In chronically sensitized 290 
mice, low intensity aerobic exercise however reduced the exacerbatory effect of creatine (26). 291 
The divergence in findings may be explained by the intensity of exercise. Indeed, there is a 292 
growing body of evidence of positive effects of regular physical activity on AHR in the general 293 
population (27) and on airway inflammation (28) and health-related quality of life in patients 294 
with asthma (29), yet a detrimental effect of repeated, intensive physical training on the airways 295 
of elite athletes (30,31).   296 
 297 
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At a cellular level, the pro-inflammatory effects of creatine could be explained by an up-298 
regulation of an inflammatory cascade and by an increased infiltration of cells (including 299 
eosinophils) within the airways (9). In sensitized and non-sensitized mice, creatine 300 
supplementation has been shown to increase the epithelial expression of inducible nitric oxide 301 
synthase (9), i.e. the major determinant of FENO (32). This could therefore explain the trend for 302 
an increased FENO in the group supplemented with CM in our study. An up-regulation of the 303 
airway remodeling process was also noticed post-creatine supplementation in both groups of 304 
mice (i.e. sensitized and non-sensitized) (9). Signs of airway inflammation and remodeling (incl. 305 
goblet cells hyperplasia and over-expression of mucin) have previously been observed in 306 
bronchial biopsies of elite athletes, which were attributed to repeated exposure to high ventilation 307 
in unfavorable environments (10,11). Whether an additive inflammatory effect could have arisen 308 
due to the use of creatine supplements by some athletes is unknown.  309 
 310 
In our study, the mild, unfavorable changes in FENO were accompanied by a trend for increased 311 
airway responsiveness (as measured by the fall in FEV1 post-EVH) in the group supplemented 312 
with CM compared to the placebo. This trend became significant when atopic athletes only were 313 
entered into the analysis. As the maximum fall in FEV1 post-EVH was reduced in the atopic 314 
players following placebo but not CM supplementation, creatine could somewhat alter the 315 
natural course of airway responsiveness during a sporting season. It is not the first time that 316 
fluctuations in airway responsiveness are observed in elite athletes. Seasonal variability in the 317 
airway response to exercise has previously been noticed in elite runners (33) and elite swimmers 318 
(34), with AHR diminishing when changes in environmental conditions and/or reductions in 319 
training load limited the stress to the airways. While, in our study, the within- and between-320 
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groups differences in the fall in FEV1 post-EVH were small and did not reach clinical 321 
significance (i.e. no athletes under CM became positive for EIB post-supplementation), the 322 
duration of the intervention was relatively short (8 weeks). We cannot exclude that sub-clinical 323 
changes in airway responsiveness progress toward clinical changes (i.e. asthma or EIB) when 324 
atopic athletes ingest creatine chronically and/or do not adhere to the recommended dosage. 325 
 326 
Asthma/AHR is the most common chronic medical condition in elite sport (12,35). However, it 327 
is largely misdiagnosed in professional (17,36) and recreational sports (37). In our study, we 328 
found objective evidence of asthma and/or AHR in about one in five youth players, but none had 329 
a medical history of asthma/EIB. In slightly younger (12-14 yr old) elite soccer players, 4 out of 330 
19 (21%) players were positive for EIB when tested with EVH (15). These results therefore 331 
highlight the need for implementing screening programs for asthma/AHR in youth elite sport. 332 
This is all the more important in that cases of sudden fatal asthma exacerbations have been 333 
reported following competitive and recreational sporting activities, particularly in young (10-20 334 
years old) males (38). Considering that three out of the thirteen U18 players (23%) in our study 335 
were not able to reach the minimum recommended ventilatory threshold of 60% predicted MVV 336 
(24) during the initial EVH test [an issue reported elsewhere (15)], there is probably a need to re-337 
visit and validate the minimum required VE for EVH when testing youth athletes.  338 
 339 
While it is commonly accepted that creatine promotes muscle mass gains during resistance 340 
training (1,5), in our study, skinfold thickness was reduced post-supplementation in both groups 341 
(while body mass remained unchanged). This suggests that CM supplementation did not promote 342 
gains in muscle mass beyond the effects observed with soccer training alone. This may be 343 
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explained by the fact that i) creatine does not have a direct anabolic effect on protein synthesis 344 
(39,40) and muscle hypertrophy (41), ii) the benefits of the supplement seem mainly dependent 345 
upon an increased training workload (42) and iii) our groups were well matched for training load 346 
and players spent limited time in the gym during the supplementation period (~50 min of 347 
strength and conditioning per week). Beyond asking participants to maintain the same diet 348 
throughout the supplementation period, we were unfortunately not in a position to control their 349 
food intake; this could possibly have influenced muscle creatine content (43) and responses to 350 
the creatine supplement (5). 351 
 352 
The strength of this study is the use of a rigorous methodological approach (i.e. a stratified, 353 
randomized, double-blind, placebo-controlled, parallel-group study design) in a difficult-to-reach 354 
sporting population (i.e. elite youth athletes). One limitation that comes with inclusion of elite 355 
athletes is the relatively large dropout rate (32%). Despite recruiting the entire U18 and U21 356 
squads, only nine participants in the CM group and ten in the placebo group completed the full 357 
trial. Further, while we met our recruitment target (based on a priori sample size calculation), 358 
many of our data were largely spread (including our primary research outcome, FENO). Having 359 
asked all our participants to refrain eating and drinking for 1 h before the FENO measurements 360 
[based on the recommendations from the ATS/ERS (21)], we do not think that food and 361 
beverages could explain the large inter-individual differences in FENO. That the three 362 
participants with the highest baseline FENO values were atopic and presented the largest increase 363 
in FENO post-CM supplementation suggest that individuals with underlying atopic airway 364 
inflammation may be more responsive to the effects of creatine. However, further studies (based 365 
around additional markers of airway inflammation) are now warranted to evaluate the clinical 366 
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significance of these findings. This is particularly necessary as a 20% increase in FENO is 367 
usually recommended as cut-off (rather than 10 ppb increase used in this study) to establish the 368 
impact of an intervention in individuals with raised baseline values [i.e. FENO >50 ppb (20)].   369 
 370 
The large inter-individual difference in our primary research outcome (FENO) could also have 371 
contributed to several of our P values not quite reaching the level of significance when analyzing 372 
our mixed group of atopic and non-atopic athletes. To overcome this limitation, two steps were 373 
taken: i) effect sizes were reported, with results suggesting that our intervention (i.e. CM 374 
supplementation) had moderate-to-large effects on FENO and on the fall in FEV1 post-EVH; and 375 
ii) post-hoc analyses were conducted on atopic players only (n=15), which confirmed (or even 376 
reinforced) the original trends. Therefore, in absence of any other human-based data, we cannot 377 
exclude a possible detrimental effect of CM on the airways of elite athletes, especially in the 378 
atopic ones. 379 
 380 
Conclusion 381 
In summary, mild unfavorable changes in FENO were observed in youth elite soccer players, 382 
particularly in those with allergic sensitization, after a recommended 8-wk course of CM 383 
supplementation. This observation was coupled with a trend for the airways of athletes 384 
supplemented with CM to be slightly more responsive to dry air hyperpnoea compared to the 385 
placebo group post-supplementation. Until further work is performed on the safety profile of 386 
creatine supplements on lung function in humans, caution should prevail, and monitoring of the 387 
respiratory health of elite athletes regularly taking creatine supplements is advised.   388 
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Figure Captions  518 
Figure 1. Outline of the study design. FENO, fractional nitric oxide in exhaled air  519 
 520 
Figure 2. Fractional nitric oxide in exhaled air (FENO) in youth elite soccer players before and 521 
after 8 weeks of creatine monohydrate (squares) or placebo supplementation (circles). Open 522 
symbols represent atopic players and closed symbols represent non-atopic players. Individual 523 
and mean values (with 95% confidence intervals) are shown. Note. When atopic players only 524 
were analyzed, the P value for within-group difference in the creatine group was 0.072. 525 
 526 
Figure 3. Change in fractional nitric oxide in exhaled air (Δ FENO) in youth elite soccer players 527 
before and after 8 weeks of creatine monohydrate (squares) or placebo supplementation (circles). 528 
Open symbols represent atopic players and closed symbols represent non-atopic players. 529 
Individual and mean values (with 95% confidence intervals) are shown. Note. When atopic 530 
players only were analyzed, the P value for between-group difference was significant at 0.026. 531 
 532 
Figure 4. Pre- and post-supplementation fall in forced expiratory volume in 1 sec (FEV1) after 6 533 
min of eucapnic voluntary hyperpnoea (EVH) of dry air in youth elite soccer players 534 
supplemented for 8 weeks with creatine monohydrate (squares) or a placebo (circles). Open 535 
symbols represent atopic players and closed symbols represent non-atopic players. Individual 536 
and mean values (with 95% confidence intervals) are shown. Note. When atopic players only 537 
were analyzed, the P value for within-group difference in the placebo group was significant at 538 
0.041, and the between-group difference. 539 
Table 1. Characteristics of study participants. 
 
ID# Age 
(yr) 
Team Body 
mass 
(kg) 
Stature 
(cm) 
FEV1 
(% 
pred.) 
FVC 
(% 
pred.) 
Atopy FENO 
(ppb) 
Post-EVH 
max FEV1 
fall (%) 
Respiratory 
symptoms 
CM           
1 17 U18 79.2 180.5 102 107 - 14 6 - 
2 16 U18 77.7 184.7 94 102 + 86 27 - 
3 16 U18 74.6 187.3 104 106 + 23 8 - 
4 16 U18 77.0 176.5 121 116 + 18 1 - 
5 16 U18 68.5 175.5 102 96 + 20 2 - 
6 17 U18 68.4 168.3 93 99 + 25 5 - 
7 21 U21 79.3 184.5 115 120 - 18 5 - 
8 19 U21 74.9 179.3 101 97 + 79 19 - 
9 18 U21 81.5 183.5 108 110 + 84 9 + 
Mean 17.3 NA 75.7 180.0 104 106 NA 40.8 9.1 NA 
SD 1.7 NA 4.6 5.9 9 8 NA 31.9 8.3 NA 
Table 1
Placebo           
10 16 U18 73.8 184.3 97 91 + 14 7 - 
11 17 U18 70.7 173.0 114 104 + 21 9 - 
12 16 U18 61.3 171.1 105 99 - 17 3 - 
13 18 U18 66.0 170.8 98 98 - 35 4 - 
14 16 U18 76.7 179.0 72 79 + 62 12 + 
15 17 U18 67.0 170.5 109 100 + 17 11 - 
16 17 U18 75.7 180.4 138 127 + 34 1 - 
17 21 U21 78.1 177.5 103 100 + 18 4 - 
18 19 U21 76.2 181.9 97 105 + 48 8 - 
19 18 U21 74.4 179.0 93 91 + 18 3 - 
Mean 17.5 NA 72.0 176.8 103 99 NA 28.4 6.2 NA 
SD 1.6 NA 5.5 5.0 17 12 NA 16.1 3.7 NA 
 
Note. U18, under 18 years of age team; U21, under 21 years of age team; FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; FENO, fractional exhaled nitric oxide in exhaled air; EVH, eucapnic voluntary hyperpnoea; CM, creatine monohydrate group; SD, 
standard deviation; NA, not applicable. None of the players had a medical history of asthma and/or of exercise-induced bronchoconstriction. No 
between-group differences were noticed at study entry.  
Table 2. Resting lung function data in youth elite soccer players pre- and post-8 1 
weeks of creatine monohydrate (CM) or placebo (PLA) supplementation 2 
 3 
 CM (n=9) PLA (n=10) 
 Pre-CM Post-CM Pre-PLA Post-PLA 
FEV1 (L) 4.56 ± 0.79 4.52 ± 0.84 4.06 ± 0.76 4.04 ± 0.75 
FEV1 (% pred.)
  104 ± 9 103 ± 10 103 ± 17 101 ± 17 
FVC (L) 5.43 ± 1.03$ 5.43 ± 1.03 4.57 ± 0.78 4.58 ± 0.74 
FVC (% pred.) 106 ± 8 105 ± 8 99 ± 12 99 ± 12 
FEV1/FVC (%) 84 ± 4 83 ± 5 89 ± 6 88 ± 6 
PEF (Lsec-1) 9.73 ± 1.31 9.60 ± 1.35 9.05 ± 1.36 9.51 ± 1.51 
FEF25-75 (Lsec-1) 4.66 ± 0.97 4.51 ± 1.10 4.62 ± 1.19 4.62 ± 1. 36 
 4 
Note. Values are means ± SD. FEV1, forced expiratory volume in the first second; 5 
FVC, forced vital capacity; PEF, peak expiratory flow; FEF25-75, forced expiratory 6 
flow between 25 and 75% of FVC; % pred., % of the predicted values (37); $ trend for 7 
a higher pre-supplementation value compared to the placebo group (P=0.053). 8 
 9 
 10 
Table 2
Pre-supplementation measurements (n=25)
Atopy, FENO, lung function, airway responsiveness 
Creatine (n=13) Placebo (n=12) 
On loan (n=1)
Tonsillitis (n=1)
Asthma exacerbation (n=1)
Anterior cruciate 
ligament injury (n=1)
Broken rib (n=1)
Non-adherence (n=1)
Groin injury (n=1)
On loan (n=1)
Stopped training (n=1)
Withdrew
Recruitment (n=28) 
19 U18 and 9 U21
Randomization
Analysis
WithdrewWithdrew
Normal training regimen (n=25)
1wk loading + 7wk maintenance
Post-supplementation measurements (n=19)
FENO, lung function, airway responsiveness 
n=10n=9
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